EGFR and paronychia: The most frequently reported grade 3 or worse TRAEs included hypertension (12.0%), γ-glutamyl transferase increased (5.0%) and hyponatremia (5.0%) in the EGFR TKI plus anlotinib group and dry skin, paronychia and appetite decreased, each occurring in 8.0% patients in the EGFR TKI group (Table 2).